Key result
ATRA exacerbates anthracycline-induced cardiomyopathy in a pediatric leukemia case, causing fluctuating systolic function.
Why the study?
Cardiac disease is a significant complication of childhood oncologic therapy, with unclear effects of ATRA on anthracycline-induced cardiomyopathy.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case suggests that all-trans retinoic acid (ATRA) may exacerbate anthracycline-induced early chronic cardiomyopathy in pediatric patients.
Cardiac disease is a significant complication of childhood oncologic therapy. We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA). Despite cessation of daunomycin, she demonstrated fluctuating systolic function in relation to ATRA administration. Improvement and deterioration in systolic function on echocardiogram and serum B-natriuretic peptide levels were seen while receiving ATRA 1 week on and 1 week off, respectively, during the maintenance phase of therapy.
No takes yet. Share an insight, caveat, or question.
Mahadeo et al. (2010) conducted a case report in acute promyelocytic leukemia (n=1). daunomycin and all-trans retinoic acid (ATRA) was evaluated on symptomatic cardiomyopathy and fluctuating systolic function. Administration of ATRA exacerbated anthracycline-induced early chronic cardiomyopathy in a 14-year-old female with acute promyelocytic leukemia, causing fluctuating systolic function.
Synapse has enriched 10 related papers. Consider them for comparative context: